Ozurdex vs. Avastin (Long Island Vitreoretinal Consultants)

This identifier refers to a comparative clinical trial (NCT01412008) sponsored by **Long Island Vitreoretinal Consultants** evaluating two distinct pharmacological approaches for the treatment of **macular edema** secondary to **central retinal vein occlusion (CRVO)**. The study compares **Ozurdex** (dexamethasone intravitreal implant), a synthetic glucocorticoid that suppresses inflammation and reduces vascular permeability, against **Avastin** (bevacizumab), a recombinant humanized monoclonal antibody that inhibits **vascular endothelial growth factor (VEGF)**. Ozurdex is administered as a sustained-release biodegradable implant, while Avastin is typically given as monthly intravitreal injections. The trial was designed to assess visual acuity improvements and the total number of intraocular injections required for each treatment modality in patients with CRVO-related macular edema.

Brand names

OzurdexAvastin

Other names

z-Long Island Vitreoretinal Consultants-macular edema-central retinal vein occlusionDexamethasone intravitreal implantBevacizumabOzurdex vs Avastin for Macular Edema in CRVO